Description
Tirzide 2.5 MG (Tirzepatide) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist the first approved twincretin in its drug class supplied as a 2.5 mg solution for injection in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage) and manufactured by Everest Pharmaceuticals Ltd. in Bangladesh. Its active ingredient, tirzepatide, is the first and only approved dual GIP/GLP-1 receptor agonist, activating both the GIP receptor and the GLP-1 receptor simultaneously with a single weekly subcutaneous injection, a mechanistically unique twincretin action that produces superior improvements in glycemic control and body weight reduction compared with selective GLP-1 receptor agonists alone.
The 2.5 mg dose of tirzepatide is the reference-label initiation dose, administered subcutaneously once weekly for the first four weeks of treatment to optimize gastrointestinal tolerability before titration to the effective therapeutic maintenance dose of 5 mg or higher. In the pivotal SURPASS-2 Phase 3 trial comparing tirzepatide versus semaglutide 1 mg in 1,879 adults with type 2 diabetes mellitus inadequately controlled on metformin, tirzepatide 5 mg, 10 mg, and 15 mg produced mean HbA1c reductions of 2.01%, 2.24%, and 2.30% from baseline respectively versus 1.86% with semaglutide 1 mg, alongside body weight reductions of 7.6 kg, 9.3 kg, and 11.2 kg versus 5.7 kg with semaglutide 1 mg (all tirzepatide doses superior to semaglutide 1 mg; p<0.001 for all comparisons). Searching for Tirzide 2.5 MG Tirzepatide? Mediaid Pharmacy lists this product within its comprehensive diabetes medicines portfolio and ships it worldwide.
Basic Product Information of Tirzide 2.5 MG (Tirzepatide)
| Brand Name | Tirzide 2.5 MG (Tirzepatide) |
| Product Name | Tirzide |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist; Twincretin; Antidiabetic Agent; Incretin-Based Therapy |
| Formulation | Solution for Injection (Pre-filled Syringe) |
| Available Strength | 2.5 mg |
| Available Pack Size | 1 Pre-filled Syringe/Box (with alcohol pad & first aid bandage) |
| Primary Indications | Type 2 diabetes mellitus (T2DM) in adults as an adjunct to diet and exercise: initiation dose 2.5 mg subcutaneously once weekly for 4 weeks; titrate to 5 mg once weekly for ≥4 weeks; may further increase in 2.5 mg increments (to 7.5 mg, 10 mg, 12.5 mg, or 15 mg) every 4 weeks as needed for additional glycemic control. Maximum dose: 15 mg once weekly. Chronic weight management in adults with initial BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity. The 2.5 mg dose is the initiation dose used solely to improve tolerability; it is not expected to provide full glycemic or weight management efficacy as a maintenance dose. |
| Manufacturer | Everest Pharmaceuticals Ltd., Bangladesh |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro (tirzepatide) by Eli Lilly for type 2 diabetes; Zepbound (tirzepatide) by Eli Lilly for chronic weight management |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at 2°C to 8°C (refrigerated). Do not freeze. Protect from light. If stored at room temperature (up to 30°C/86°F), use within the period stated on the pack. Keep out of the reach of children. |
How Tirzide 2.5 MG (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism the Twincretin Mechanism
Tirzepatide, the active ingredient in Tirzide 2.5 MG, is the world’s first approved dual GIP and GLP-1 receptor agonist, a drug class defined by the simultaneous pharmacological activation of two distinct incretin hormone receptors in a single molecule administered as a once-weekly subcutaneous injection. This dual receptor agonism distinguishes tirzepatide from all previously approved incretin-based therapies including liraglutide, semaglutide, dulaglutide, and exenatide each of which functions exclusively as a selective GLP-1 receptor agonist (GLP-1 RA). Tirzepatide activates the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor with balanced potency, acting as a single-molecule pharmacological analog of both endogenous incretin hormones simultaneously.
GIP and GLP-1 are both gut-derived peptide hormones released postprandially from intestinal K-cells and L-cells respectively; together they constitute the physiological incretin system that accounts for 50 to 70% of postprandial insulin secretion in healthy individuals, a glucose-stimulated response markedly impaired in type 2 diabetes mellitus (T2DM). In T2DM, the incretin effect is substantially reduced, with GLP-1-mediated insulin secretion diminished and GIP-mediated insulin secretion essentially absent due to GIP receptor desensitization under chronic hyperglycemia, making pharmacological restoration of both incretin signaling pathways through tirzepatide’s dual agonism a mechanistically rational approach to comprehensive glycemic correction.
Tirzepatide’s GLP-1 receptor agonism drives four synergistic antidiabetic effects: (1) glucose-dependent stimulation of pancreatic beta-cell insulin secretion meaning insulin release occurs only when plasma glucose is elevated, mechanistically protecting against hypoglycemia; (2) glucose-dependent suppression of pancreatic alpha-cell glucagon secretion, reducing postprandial hepatic glucose output; (3) slowing of gastric emptying, which blunts the postprandial glucose excursion; and (4) hypothalamic appetite suppression and reduction in caloric intake through central GLP-1 receptor activation in the arcuate nucleus and hindbrain nuclei. Tirzepatide’s GIP receptor agonism contributes complementary metabolic effects: GIP receptor activation in pancreatic beta-cells further amplifies glucose-dependent insulin secretion through a cAMP-PKA signaling pathway pharmacologically distinct from GLP-1 receptor signaling, producing an additive insulin secretagogue effect.
GIP receptor activation in adipocytes modulates lipid metabolism through promotion of lipoprotein lipase-mediated triglyceride clearance from circulation and enhancement of fatty acid re-esterification, effects that may contribute to the superior body weight reduction observed with tirzepatide versus selective GLP-1 RAs by altering adipose tissue energy handling. The synergistic interaction between simultaneous GIP and GLP-1 receptor activation explains why tirzepatide produces statistically greater HbA1c reductions and body weight losses than have been observed with any approved selective GLP-1 RA at its maximally titrated dose, including semaglutide 1 mg and 2 mg a pharmacodynamic advantage directly attributable to the twincretin mechanism rather than to any dose-related artifact. Clinicians managing complex diabetes and weight cases can review the full range of tirzepatide medicines at Mediaid Pharmacy for their therapeutic programs.
Tirzide 2.5 MG delivers the 2.5 mg initiation dose of tirzepatide the reference-label starting dose prescribed subcutaneously once weekly for the first four weeks of treatment exclusively to allow the gastrointestinal tract to adapt to tirzepatide’s pharmacological effects, most notably gastric emptying slowing, before progressing to the first therapeutic maintenance dose of 5 mg. At 2.5 mg once weekly, one box of Tirzide 2.5 MG (1 pre-filled syringe per box) provides a single-week supply appropriate to the prescribed weekly injection schedule. Structural evidence from cryo-electron microscopy studies confirms that tirzepatide adopts distinctly different conformations at the GIP receptor versus the GLP-1 receptor, engaging each receptor through receptor-specific molecular contacts that maximize potency at both sites rather than compromising binding affinity at either.
The long-acting pharmacokinetic profile of tirzepatide a plasma half-life of approximately 5 days achieved through fatty acid conjugation and albumin binding, the same engineering approach used for semaglutide supports once-weekly subcutaneous dosing with a pre-filled syringe, eliminating daily injection requirements and enabling a more convenient treatment schedule for adults with T2DM. For healthcare providers seeking companion antidiabetic agents, supportive medications, or insulin formulations alongside tirzepatide therapy, the diabetes medicines portfolio at Mediaid Pharmacy offers a comprehensive selection available for worldwide delivery.
In the landmark SURPASS-2 Phase 3 randomized, open-label trial the first head-to-head comparison of a dual GIP/GLP-1 receptor agonist versus a selective GLP-1 receptor agonist tirzepatide 5 mg, 10 mg, and 15 mg each produced statistically significantly greater HbA1c reductions (–2.01%, –2.24%, –2.30% respectively) and body weight reductions (–7.6 kg, –9.3 kg, –11.2 kg respectively) than semaglutide 1 mg (–1.86% HbA1c; –5.7 kg weight) in 1,879 adults with T2DM on background metformin at 40 weeks (p<0.001 for all tirzepatide doses vs. semaglutide for both co-primary endpoints). Across the entire SURPASS program SURPASS-1 through SURPASS-5 tirzepatide at its maintenance doses consistently achieved HbA1c reductions of 1.87% to 2.58% from baseline, with 81% to 92% of tirzepatide 15 mg-treated patients achieving HbA1c below 7.0%, the standard glycemic target for T2DM management.
Approved Indications of Tirzepatide (Reference Label for Tirzide 2.5 MG (Tirzepatide))
Tirzepatide, the active ingredient in Tirzide 2.5 MG, carries reference-label indications across two distinct clinical settings: glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The 2.5 mg tablet strength of Tirzide directly supports the mandatory initiation phase of tirzepatide therapy in both indications a single 2.5 mg subcutaneous injection once weekly for four weeks before the prescriber titrates to the first maintenance dose. Both indications require the same initiation dose and titration schedule beginning with 2.5 mg once weekly. Prescribers should confirm the exact locally approved indications on the Tirzide product label and applicable national endocrinology and diabetes guidelines before initiating treatment.
|
Type 2 Diabetes Mellitus Initiation with Tirzepatide 2.5 mg Once Weekly Indicated for adults with type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control. The tirzepatide prescribing program begins with 2.5 mg subcutaneously once weekly for 4 weeks (the initiation dose to improve gastrointestinal tolerability), followed by titration to 5 mg once weekly as the first maintenance dose, with further optional titration in 2.5 mg increments every 4 weeks (to 7.5 mg, 10 mg, 12.5 mg, or 15 mg maximum) based on individual glycemic response and tolerability. The 2.5 mg initiation dose is not expected to provide full glycemic efficacy independently; clinical benefit in T2DM is delivered at maintenance doses of 5 mg and above, as demonstrated across the SURPASS-1 through SURPASS-5 Phase 3 program. For additional antidiabetic agents used alongside tirzepatide, browse the diabetes medicines collection at Mediaid Pharmacy. |
Chronic Weight Management Obesity and Overweight with Weight-Related Comorbidities Indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with initial BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. In the SURMOUNT-1 Phase 3 trial (n=2,539 adults without T2DM), tirzepatide 15 mg produced a mean body weight reduction of 22.5% from baseline versus 2.4% with placebo at 72 weeks the largest weight reduction ever demonstrated in a randomized controlled trial of a pharmacological agent with 48% of participants achieving ≥25% body weight loss on tirzepatide 15 mg versus 1% on placebo. The same 2.5 mg initiation dose and up-titration schedule applies in the weight management indication. For the complete tirzepatide medicines range, visit the tirzepatide medicines portfolio at Mediaid Pharmacy. |
Key Clinical Benefits of Tirzide 2.5 MG (Tirzepatide)
|
Superior HbA1c Reduction Versus All Approved Comparators Across the SURPASS Program Tirzepatide demonstrated statistically superior HbA1c reductions versus every approved active comparator tested in the Phase 3 SURPASS program. In SURPASS-2 (vs. semaglutide 1 mg), tirzepatide 5/10/15 mg achieved HbA1c reductions of 2.01%/2.24%/2.30% versus 1.86% (p<0.001 all doses). In SURPASS-3 (vs. insulin degludec), tirzepatide 5/10/15 mg achieved 1.93%/2.20%/2.37% HbA1c reduction versus 1.34% with insulin degludec (p<0.001 all doses), with 81% to 92% of patients achieving HbA1c below 7.0% on tirzepatide maintenance doses. These results establish tirzepatide as the most effective HbA1c-lowering drug class approved in T2DM, driven by its unique dual GIP and GLP-1 receptor agonism that no selective incretin therapy replicates. |
Clinically Unprecedented Body Weight Reduction Up to 22.5% in Non-Diabetic Obesity Tirzepatide produces clinically meaningful, dose-dependent body weight reductions beyond those observed with any prior pharmacological treatment for either T2DM or obesity. In the T2DM setting (SURPASS-2), tirzepatide 15 mg produced a mean –11.2 kg weight reduction versus –5.7 kg with semaglutide 1 mg at 40 weeks. In the obesity/weight management setting (SURMOUNT-1), tirzepatide 15 mg produced a mean weight loss of 22.5% from baseline (approximately 23.6 kg absolute reduction) versus 2.4% with placebo at 72 weeks the largest weight loss ever recorded in a pharmacological obesity trial. In adults with T2DM and obesity (SURMOUNT-2), tirzepatide 15 mg produced 15.7% weight loss versus 3.3% with placebo. This degree of weight reduction approaches outcomes achievable with bariatric surgery, fundamentally repositioning tirzepatide in the cardiometabolic treatment landscape. |
Once-Weekly Pre-filled Syringe Dosing with Structured Titration Supporting Long-Term Adherence Tirzide 2.5 MG is supplied in a ready-to-use pre-filled syringe requiring no vial preparation, dose calculation, or insulin pen dialing the patient or caregiver injects the entire contents of the syringe subcutaneously once weekly into the abdomen, thigh, or upper arm. The once-weekly injection schedule dramatically reduces the treatment burden versus daily injectable therapies (such as liraglutide or basal insulin) and supports long-term adherence in patients managing chronic T2DM or obesity. The 2.5 mg initiation dose specifically reduces gastrointestinal side effects (nausea, vomiting, diarrhea) during the critical first four weeks of treatment, improving tolerability and significantly reducing early discontinuation driven by GI intolerance the primary barrier to patient persistence on incretin-based therapies. Each box contains 1 pre-filled syringe with an alcohol pad and first aid bandage, providing a complete single-injection kit. |
Drug Interactions and Important Safety Information for Tirzide 2.5 MG (Tirzepatide)
The most clinically significant drug interaction categories for tirzepatide involve insulin and insulin secretagogues, orally administered medications with narrow absorption windows, and agents affecting glycemic control. Unlike many oral antidiabetic drugs, tirzepatide is not metabolized by hepatic CYP450 enzymes; it undergoes proteolytic degradation of the peptide backbone at multiple sites, C-terminal fatty acid chain metabolism via beta-oxidation and omega-oxidation, and renal clearance of small metabolite fragments a metabolic pathway with no clinically relevant CYP enzyme drug-drug interactions, making tirzepatide pharmacokinetically simpler than most oral antidiabetic agents in terms of CYP-mediated interaction risk. However, several mechanism-based and pharmacodynamic interactions require clinical attention before and throughout Tirzide 2.5 MG therapy.
Insulin and insulin secretagogues (sulfonylureas and meglitinides) are the most clinically consequential drug interaction partners for tirzepatide. Co-administration of tirzepatide with basal insulin, prandial insulin, or pre-mixed insulin formulations significantly increases the risk of hypoglycemia, particularly during the first weeks of combined therapy when tirzepatide’s incretin effects on insulin secretion are being established alongside existing insulin doses; insulin dose reductions of 20 to 40% are frequently required when tirzepatide is added to an insulin regimen, and frequent blood glucose self-monitoring is mandatory during the dose-overlap period. Sulfonylureas (including glibenclamide, glipizide, and glimepiride) and meglitinides (repaglinide, nateglinide) stimulate insulin secretion via ATP-sensitive potassium channel blockade in a glucose-independent mechanism, and their combination with tirzepatide further increases hypoglycemia risk; dose reduction of the sulfonylurea or meglitinide should be considered when tirzepatide is initiated or dose-escalated.
Orally administered medications with time-sensitive pharmacokinetic profiles (narrow therapeutic index drugs, medications where Cmax and Tmax matter clinically) must be used with caution during tirzepatide initiation and dose escalation: tirzepatide slows gastric emptying, potentially reducing the rate of absorption (Cmax and time to Cmax) of co-administered oral drugs without necessarily affecting the total amount absorbed (AUC), an interaction most clinically relevant for oral hormonal contraceptives (where Cmax reduction may transiently affect contraceptive efficacy during dose escalation; the use of a barrier contraceptive method for 4 weeks after each tirzepatide dose increase is recommended for women using oral hormonal contraceptives), oral antibiotics requiring rapid absorption, and levothyroxine. Clinicians co-prescribing companion antidiabetic medications or cardiovascular risk reduction agents alongside tirzepatide can browse the complete diabetes medicines range available at Mediaid Pharmacy.
Warfarin and other oral anticoagulants with narrow therapeutic windows (vitamin K antagonists) may show altered pharmacokinetics when gastric emptying is slowed by tirzepatide; INR should be monitored more frequently after tirzepatide initiation and at each dose escalation step. Alcohol potentiates the risk of hypoglycemia, particularly in patients on concomitant insulin or sulfonylurea therapy, and patients should be counseled to limit alcohol consumption throughout Tirzide 2.5 MG treatment. Corticosteroids (oral, injectable, and high-potency topical formulations) antagonize tirzepatide’s glycemic effects by inducing insulin resistance and promoting hepatic glucose output; glucose monitoring should be intensified when corticosteroid therapy is initiated or discontinued in a patient receiving tirzepatide, and temporary antidiabetic dose adjustments may be required.
Sympathomimetics (including epinephrine, pseudoephedrine, and albuterol) can elevate blood glucose and mask signs of hypoglycemia; their concomitant use requires patient education and increased glucose monitoring. Patients must disclose their complete medication list including all prescription drugs, over-the-counter products, vitamins, and herbal supplements to their prescribing endocrinologist or diabetologist before and throughout Tirzide 2.5 MG treatment. Providers sourcing insulin formulations or other antidiabetic agents alongside Tirzide can explore the full Everest Pharmaceuticals medicines range at Mediaid Pharmacy.
Side Effects and Precautions of Tirzide 2.5 MG (Tirzepatide)
|
Common Side Effects Nausea (the most frequently reported adverse event; typically mild to moderate in severity; most common during initiation and dose escalation; attenuates with continued treatment; directly addressed by starting at 2.5 mg) Diarrhea (second most common GI adverse event; may be transient during initiation; usually resolves without dose modification) Vomiting (reported more frequently during dose escalation; patients should be advised to eat slowly and in smaller portions) Constipation (particularly at higher maintenance doses; dietary fiber intake and hydration counseling recommended) Decreased appetite and reduced food intake (a pharmacodynamic effect contributing to weight reduction; patients may require nutritional monitoring) Abdominal pain and dyspepsia (typically mild; self-limiting in most patients) Injection site reactions (erythema, pruritus, or swelling at the injection site; rotate injection sites with each weekly dose) Hypoglycemia (predominantly when combined with insulin or sulfonylurea; rare as monotherapy) Belching, flatulence, and gastroesophageal reflux (reported less frequently; attributable to gastric emptying delay) |
Serious Warnings and Precautions Thyroid C-cell tumors (medullary thyroid carcinoma risk): tirzepatide caused dose-dependent thyroid C-cell tumors (including carcinoma) in rodent studies. Relevance to humans is unknown. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Patients should be counseled on the risk and instructed to report symptoms of thyroid tumors (neck mass, dysphagia, hoarseness, dyspnea) promptly. Monitoring with serum calcitonin or thyroid ultrasound is not routinely recommended but may be considered in individual cases. Pancreatitis: acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported with GLP-1 receptor agonists. Discontinue tirzepatide promptly if pancreatitis is suspected (persistent severe abdominal pain, nausea, vomiting, elevated serum lipase or amylase). Do not restart Tirzide 2.5 MG if pancreatitis is confirmed. Patients with a history of pancreatitis should be evaluated carefully before starting tirzepatide therapy. Acute kidney injury (AKI): nausea, vomiting, and diarrhea can cause dehydration, precipitating AKI in susceptible patients. Withhold tirzepatide in patients who experience significant GI adverse events until rehydrated and renally stable. Monitor renal function before tirzepatide initiation and during dose escalation in patients at risk for renal impairment. Diabetic retinopathy complications: rapid improvement in glycemic control has been associated with a temporary worsening of diabetic retinopathy. Patients with pre-existing diabetic retinopathy should undergo ophthalmological evaluation before starting tirzepatide and be monitored during treatment. Hypersensitivity reactions: serious hypersensitivity reactions (including anaphylaxis, angioedema) have been reported with tirzepatide. Permanently discontinue Tirzide 2.5 MG if a serious hypersensitivity reaction occurs. Patients with known hypersensitivity to tirzepatide or any excipient should not receive this product. Embryo-fetal toxicity: tirzepatide may cause fetal harm. Females of reproductive potential should use effective contraception during Tirzide 2.5 MG treatment and for at least 2 weeks after the final dose (consistent with the approximately 5-day half-life and tissue clearance timeline). Tirzepatide should be discontinued at least 2 months before a planned pregnancy. Breastfeeding is not recommended during treatment. Consult a prescribing endocrinologist or obstetrician before initiating tirzepatide if pregnant, planning pregnancy, or currently breastfeeding. |
Who Should Use Tirzide 2.5 MG (Tirzepatide)?
Tirzide 2.5 MG (Tirzepatide) is the mandatory starting product for all adults initiating tirzepatide therapy whether for type 2 diabetes mellitus (T2DM) or chronic weight management as the 2.5 mg dose constitutes the reference-label initiation dose that every patient must receive for the first four weeks of treatment before titration to the first maintenance dose of 5 mg. Tirzide 2.5 MG is therefore indicated for: (1) adults with T2DM inadequately controlled with diet and exercise alone or with existing oral antidiabetic agents or insulin, for whom tirzepatide is being introduced as an add-on or replacement therapy component by their prescribing endocrinologist or diabetologist; (2) adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (hypertension, dyslipidemia, T2DM, obstructive sleep apnea, or cardiovascular disease) for whom chronic weight management with tirzepatide has been prescribed; and (3) patients transitioning from another GLP-1 receptor agonist or incretin-based therapy to tirzepatide, where the 2.5 mg initiation dose provides the gastrointestinal adaptation period regardless of prior incretin exposure.
Tirzide 2.5 MG is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, type 1 diabetes mellitus (T1DM), and individuals with known hypersensitivity to tirzepatide or any product excipient. Before initiating Tirzide 2.5 MG, prescribers should evaluate baseline HbA1c and fasting plasma glucose, renal function (eGFR), body weight and BMI, cardiovascular risk profile, diabetic retinopathy status, and personal/family thyroid history. Injection site rotation counseling (abdomen, thigh, or upper arm; rotating within each site) and patient education on the weekly injection schedule and proper pre-filled syringe technique are required before the first dose. For patients requiring companion antidiabetic agents, cardiovascular medicines, or the broader Everest Pharmaceuticals product range alongside their tirzepatide regimen, the Mediaid Pharmacy Everest Pharmaceuticals medicines portfolio and the comprehensive diabetes medicines collection offer a complete selection available for worldwide delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tirzide 2.5 MG (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty and diabetes medicines with worldwide shipping. Tirzide 2.5 MG (Tirzepatide), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, is available as 1 pre-filled syringe per box (with alcohol pad and first aid bandage), and all orders are supported by pricing quotations, stock confirmation, regulatory documentation, and end-to-end delivery tracking. Endocrinology clinics, diabetology centers, hospitals, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries about Tirzide 2.5 MG Tirzepatide stock, pricing, and international delivery timelines to their country. Buyers initiating tirzepatide prescribing programs, sourcing the initiation dose for new patient starts, or co-sourcing multiple diabetes medicines in a single consolidated shipment can browse the complete tirzepatide medicines collection and the broader diabetes medicines collection at Mediaid Pharmacy before requesting a consolidated quotation.
Why Choose Tirzide 2.5 MG (Tirzepatide) from Mediaid Pharmacy?
Tirzide 2.5 MG (Tirzepatide) provides endocrinologists, diabetologists, and obesity medicine specialists with the reference-label 2.5 mg initiation dose of tirzepatide the foundational starting strength prescribed for every new patient beginning tirzepatide therapy, as mandated by the reference prescribing information for both the T2DM and chronic weight management indications. The 2.5 mg initiation phase is clinically critical: it allows the gastrointestinal system to adapt progressively to tirzepatide’s gastric emptying-slowing effects, significantly reducing the severity and frequency of nausea, vomiting, and diarrhea that are the primary drivers of early treatment discontinuation in the incretin therapy class, thereby protecting long-term patient adherence to a treatment regimen that delivers its peak glycemic and weight management benefits only at maintenance doses of 10 to 15 mg sustained over months of continuous weekly therapy. Tirzide 2.5 MG is manufactured by Everest Pharmaceuticals Ltd., a Bangladesh-based pharmaceutical manufacturer, and is supplied in an individually boxed pre-filled syringe pack with alcohol pad and first aid bandage a complete, ready-to-inject kit suited to the once-weekly subcutaneous administration schedule required for both T2DM and weight management indications. Mediaid Pharmacy supplies Tirzide 2.5 MG with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka, with every order beginning from a prescription-based inquiry that aligns supply with clinical need. To source additional tirzepatide strengths, Everest Pharmaceuticals-branded medicines, or a comprehensive diabetes medicine panel alongside Tirzide 2.5 MG, visit the Mediaid Pharmacy Everest Pharmaceuticals medicines section and contact the team for a personalized quotation.
Frequently Asked Questions About Tirzide 2.5 MG (Tirzepatide)
What is Tirzide 2.5 MG (Tirzepatide) used for?
Tirzide 2.5 MG (Tirzepatide) is a dual GIP and GLP-1 receptor agonist (twincretin) used to initiate tirzepatide therapy in adults with type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise for improved glycemic control, and in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity for chronic weight management. The 2.5 mg dose is the mandatory reference-label initiation dose for the first four weeks of treatment, prescribed to improve gastrointestinal tolerability before titration to the first maintenance dose of 5 mg. Tirzepatide activates both the GIP receptor and the GLP-1 receptor simultaneously, producing superior HbA1c reductions and body weight losses compared with all approved selective GLP-1 receptor agonists as demonstrated in the SURPASS and SURMOUNT Phase 3 trial programs. Tirzide 2.5 MG is available at Mediaid Pharmacy and ships worldwide.
What is the generic name of Tirzide 2.5 MG?
The generic name of Tirzide 2.5 MG is tirzepatide INN. The product name listed in the Everest Pharmaceuticals Ltd. catalog is Tirzide. Tirzide 2.5 MG is a solution for injection formulated in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh. The originator reference brand for tirzepatide is Mounjaro (for T2DM) and Zepbound (for chronic weight management), both developed and commercialized by Eli Lilly and Company. Mediaid Pharmacy distributes Tirzide 2.5 MG globally with worldwide shipping to patients and healthcare providers.
How is Tirzide 2.5 MG (Tirzepatide) administered?
Tirzide 2.5 MG (Tirzepatide) is administered as a subcutaneous injection once weekly into the abdomen, thigh, or upper arm. The pre-filled syringe is ready to use without reconstitution, dose calculation, or pen dialing. Inject on the same day each week at approximately the same time; if a dose is missed and it is 4 or more days before the next scheduled dose, inject the missed dose as soon as possible; if fewer than 4 days remain until the next scheduled dose, skip the missed dose and resume the regular weekly schedule do not administer two doses within 3 days of each other. Rotate injection sites within the chosen anatomical location (abdomen, thigh, or upper arm) with each weekly injection to minimize injection site reactions. Tirzide 2.5 MG may be taken with or without food; there is no fasting requirement for tirzepatide unlike some other antidiabetic injectable agents. Store the unused pre-filled syringe refrigerated at 2°C to 8°C and allow it to reach room temperature before injecting for improved comfort.
Is the 2.5 mg dose the maintenance dose for tirzepatide?
No. The 2.5 mg dose of tirzepatide is exclusively the initiation dose, prescribed for the first four weeks of treatment only to allow gastrointestinal adaptation and minimize nausea, vomiting, and diarrhea during the early treatment period. The 2.5 mg dose is not expected to provide clinically meaningful glycemic efficacy or substantial weight reduction as a maintenance dose. After the 4-week initiation period, the dose is increased to 5 mg once weekly the first maintenance dose and may be further increased in 2.5 mg increments every 4 weeks (to 7.5 mg, 10 mg, 12.5 mg, or 15 mg) based on glycemic response and tolerability, up to a maximum of 15 mg once weekly. Continuing at 2.5 mg long-term without titrating to a maintenance dose is clinically inappropriate; all prescribers should plan the full titration schedule at treatment initiation and counsel patients accordingly.
What is the difference between Tirzide (Tirzepatide) and Mounjaro (Tirzepatide)?
Tirzide (tirzepatide) manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and Mounjaro (tirzepatide) manufactured by Eli Lilly and Company contain the same active ingredient, tirzepatide INN, as a subcutaneous injection for once-weekly administration. Mounjaro is the originator brand name approved by the FDA for tirzepatide in type 2 diabetes mellitus; Zepbound is the Eli Lilly brand name for tirzepatide in chronic weight management. Tirzide 2.5 MG is the Everest Pharmaceuticals-branded formulation supplied in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage) distributed globally by Mediaid Pharmacy. The same reference initiation dose (2.5 mg once weekly for 4 weeks) and titration schedule apply to Tirzide as to the originator brands. Confirm prescribing requirements and local regulatory status with your treating endocrinologist and the relevant regulatory authority in your country before initiating Tirzide 2.5 MG therapy.
What are the side effects of Tirzide 2.5 MG (Tirzepatide)?
The most common side effects of tirzepatide are gastrointestinal in nature: nausea (the most frequently reported adverse event, typically mild to moderate and most pronounced during initiation and dose escalation the primary reason the 2.5 mg starting dose exists), diarrhea, vomiting, constipation, abdominal pain, decreased appetite, dyspepsia, and belching. These GI effects generally diminish with continued treatment and are substantially mitigated by the structured 4-week initiation period at 2.5 mg before titration. Injection site reactions (redness, itching, swelling) occur in some patients and are managed by rotating injection sites. Hypoglycemia is uncommon as monotherapy but significantly increased when tirzepatide is combined with insulin or sulfonylureas. Serious but less common adverse effects include acute pancreatitis, acute kidney injury secondary to dehydration from GI side effects, hypersensitivity reactions (including anaphylaxis and angioedema), worsening of diabetic retinopathy, and based on rodent studies a theoretical risk of thyroid C-cell tumors (medullary thyroid carcinoma), leading to contraindication in patients with personal or family history of MTC or MEN2. Consult your prescribing endocrinologist or diabetologist about your individual risk profile before and during treatment with Tirzide 2.5 MG.
Is Tirzide 2.5 MG (Tirzepatide) safe during pregnancy or while breastfeeding?
No. Tirzepatide may cause fetal harm based on its mechanism of action, with adverse effects on fetal development observed in animal reproduction studies. Tirzide 2.5 MG is not recommended for use during pregnancy. Females of reproductive potential must use effective non-hormonal contraception (or hormonal contraception plus a barrier method during dose escalation, given tirzepatide’s gastric emptying-slowing effect on oral contraceptive absorption) during treatment and for at least 2 weeks after the final dose, consistent with the approximate 5-day plasma half-life and post-dose clearance timeline. Because tirzepatide takes approximately 4 to 5 half-lives (approximately 25 days) to be substantially cleared from plasma, and given the longer time required for complete tissue clearance, prescribers recommend discontinuing tirzepatide at least 2 months before a planned pregnancy. Breastfeeding is not recommended during treatment. Speak with your prescribing endocrinologist or obstetrician before starting Tirzide 2.5 MG if you are pregnant, planning a pregnancy, or currently breastfeeding.
Can I order Tirzide 2.5 MG (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Tirzide 2.5 MG (Tirzepatide) to patients and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Tirzide 2.5 MG (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.